|158.59||-2.33||-1.45%||Vol 650.37K||1Y Perf -55.20%|
|Aug 11th, 2022 16:00 DELAYED|
|- -||0.52 0.33%|
|Target Price||240.70||Analyst Rating||Moderate Buy 2.20|
|Potential %||51.78||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★★★ 64.58|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★★★★ 85.44|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||★★★★+ 56.55|
|Price Range Ratio 52W %||11.97||Earnings Rating||—|
|Market Cap||38.49B||Earnings Date||8th Aug 2022|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||7.69|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.83M|
|Avg. Monthly Volume||1.00M|
|Avg. Quarterly Volume||1.15M|
BioNTech SE (NASDAQ: BNTX) stock closed at 158.59 per share at the end of the most recent trading day (a -1.45% change compared to the prior day closing price) with a volume of 650.37K shares and market capitalization of 38.49B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1310 people. BioNTech SE CEO is Ugur Sahin.
The one-year performance of BioNTech SE stock is -55.2%, while year-to-date (YTD) performance is -38.48%. BNTX stock has a five-year performance of %. Its 52-week range is between 117.08 and 464, which gives BNTX stock a 52-week price range ratio of 11.97%
BioNTech SE currently has a PE ratio of 2.90, a price-to-book (PB) ratio of 2.55, a price-to-sale (PS) ratio of 1.96, a price to cashflow ratio of 8.30, a PEG ratio of 2.32, a ROA of 104.99%, a ROC of 136.38% and a ROE of 139.59%. The company’s profit margin is 56.00%, its EBITDA margin is 79.50%, and its revenue ttm is $19.92 Billion , which makes it $81.97 revenue per share.
Of the last four earnings reports from BioNTech SE, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $7.69 for the next earnings report. BioNTech SE’s next earnings report date is -.
The consensus rating of Wall Street analysts for BioNTech SE is Moderate Buy (2.2), with a target price of $240.7, which is +51.78% compared to the current price. The earnings rating for BioNTech SE stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BioNTech SE has a dividend yield of 0.00% with a dividend per share of $0.00 and a payout ratio of -%.
BioNTech SE has a Sell technical analysis rating based on Technical Indicators (ADX : 13.87, ATR14 : 8.71, CCI20 : -53.86, Chaikin Money Flow : 0.26, MACD : 2.43, Money Flow Index : 47.31, ROC : -0.71, RSI : 38.93, STOCH (14,3) : 15.12, STOCH RSI : 0.10, UO : 51.14, Williams %R : -84.88), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BioNTech SE in the last 12-months were:
Fri, 15 Jul 2022 16:48 GMT BioNTech SE (BNTX) Gets a Hold Rating from Morgan Stanley- TipRanks. All rights reserved.
Mon, 11 Jul 2022 10:16 GMT BioNTech SE (BNTX) Gets a Buy Rating from H.C. Wainwright- TipRanks. All rights reserved.
Wed, 06 Jul 2022 10:25 GMT Analysts Are Bullish on Top Healthcare Stocks: BioNTech SE (BNTX), Ayala Pharmaceuticals (AYLA)- TipRanks. All rights reserved.
Thu, 30 Jun 2022 10:16 GMT BioNTech SE (BNTX) Receives a Hold from UBS- TipRanks. All rights reserved.
Mon, 27 Jun 2022 15:21 GMT BioNTech Gains on COVID-19 News, but is There More Afoot- TipRanks. All rights reserved.
Mon, 27 Jun 2022 10:05 GMT BioNTech SE (BNTX) Receives a Buy from Berenberg Bank- TipRanks. All rights reserved.
Tue, 24 May 2022 12:47 GMT BioNTech SE (BNTX) Gets a Hold Rating from Goldman Sachs- TipRanks. All rights reserved.
Mon, 09 May 2022 21:15 GMT BioNTech SE (BNTX) Gets a Hold Rating from J.P. Morgan- TipRanks. All rights reserved.
Thu, 31 Mar 2022 09:55 GMT BioNTech SE (BNTX) Receives a Hold from J.P. Morgan- TipRanks. All rights reserved.
Wed, 30 Mar 2022 13:53 GMT BioNTechs Q4 Earnings Impress Investors- TipRanks. All rights reserved.
Fri, 18 Mar 2022 13:55 GMT BioNTech SE (BNTX) Receives a Hold from Jefferies- TipRanks. All rights reserved.
Wed, 02 Mar 2022 09:11 GMT Understanding Pfizers Newly Added Risk Factors- TipRanks. All rights reserved.
Mon, 07 Feb 2022 11:25 GMT Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and Genmab (GMAB)- TipRanks. All rights reserved.
Wed, 12 Jan 2022 14:45 GMT BioNTech SE (BNTX) Receives a Hold from Goldman Sachs- TipRanks. All rights reserved.
Tue, 04 Jan 2022 11:15 GMT Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Zynex (ZYXI) and Edesa Biotech (EDSA)- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.